Markets

Takeda and Resolve Join Forces - Analyst Blog

Takeda Pharmaceutical Company Limited ( TKPYY ) recently entered into a collaboration agreement with privately held biotechnology company, Resolve Therapeutics, for the development of treatments for lupus including systemic lupus erythematosus (SLE) and other autoimmune diseases.

Resolve Therapeutics' pipeline includes RSLV-132 and several other candidates in the pre-clinical proof-of-concept stage. RSLV-132 is expected to enter clinical development during the course of the year for SLE.

As per the terms of the agreement, Takeda will make an initial payment of $8 million to Resolve Therapeutics for the development of RSLV-132. Resolve Therapeutics will be entirely responsible for the development of RSLV-132 and other candidates under the collaboration till the completion of first phase Ib/IIa trial, after which Takeda has an option to license the candidates.

If Takeda elects to exercise this option for any candidate, the company will bear the lead responsibility for its global development and commercialization. Upon exercising this option, Takeda will be obligated to pay an option exercise fee and additional development milestones of approximately $247 million to Resolve Therapeutics. Apart from this, Takeda will also pay royalties on the net sales of products developed under this collaboration.

We note that last month, Takeda suffered a setback when the company along with partner Affymax, Inc. ( AFFY ) recalled all lots of Omontys (peginesatide) voluntarily. The recall was prompted by data from post-marketing studies which revealed that fatal reactions including anaphylaxis were found to be associated with the use of Omontys. Omontys received approval in the US, in Mar 2012, for the treatment of anemia due to chronic kidney disease (CKD) in adult patients on dialysis.

Takeda Pharma carries a Zacks Rank #3 (Hold). Lannett Company, Inc. ( LCI ) and Cytokinetics, Incorporated ( CYTK ) look more attractive in the pharma sector. Both carry a Zacks Rank #1 (Strong Buy).

AFFYMAX INC (AFFY): Free Stock Analysis Report

CYTOKINETCS INC (CYTK): Free Stock Analysis Report

LANNETT INC (LCI): Free Stock Analysis Report

TAKEDA PHARMACT (TKPYY): Get Free Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CYTK LCI

Other Topics

Stocks

Latest Markets Videos

Zacks

Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

Learn More